Address	722 High Street Melbourne Victoria (VIC) 3102 Australia
Employees	-
Website	http://www.inviongroup.com
Updated	07/08/2019
Invion Ltd. engages in the development of treatments for respiratory and autoimmune disease. It develops the following drug assets: nadolol, zafirlukast, and ala-Cpn10. The company was founded on October 11, 2000 and is headquartered in Chermside, Australia.